Earnings Releases·Oct 29, 2026, 4:07 PM ET

Merit Medical Systems — Third Quarter 2026 Earnings Summary

Revenue reached $416.2 million for the quarter, an 8.4% year-over-year increase, while GAAP net income rose 51% to $42.3 million ($0.70 per share) and non-GAAP net income increased 22% to $67.4 million ($1.12 per share).
Management raised full-year 2026 revenue guidance to $1.635 billion–$1.642 billion and non-GAAP EPS guidance to $4.33–$4.37, citing better-than-expected demand and 9% constant currency organic growth.
The Therapeutic segment drove strong performance with 14% year-over-year growth, led by 33% gains in Endoscopy and 32% in OEM revenue, while the Foundational segment grew 6%.
Balance sheet strength is evident with $503.6 million in cash and cash equivalents and $129.5 million in year-to-date free cash flow, alongside stable total debt obligations of $747.5 million.
Future outlook includes finalizing a long-term strategic plan for sustainable growth, while risks remain regarding the integration of recent acquisitions (Solo Pace, View Point, C2, Biolife) and geopolitical or trade policy uncertainties.